The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback